Terazosin Capsule
Product Images NDC 71335-3131

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71335-3131). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 01)

Two line graphs from a study measuring Terazosin effects. The left graph shows mean change in total symptom score from baseline over three months, comparing Terazosin and placebo groups. The right graph shows mean increase in peak flow rate (mL/sec) from baseline over three months for the same groups. Error bars and sample sizes are indicated.*

FDA Label Image

Image Description (Figure 02)

A line graph showing the mean change in total symptom score from baseline over 30 months in a long-term, open-label, non-placebo controlled study of 494 participants. The vertical axis represents mean change from baseline, and the horizontal axis shows time in months, indicating a general decrease in symptom scores over the study period.*

FDA Label Image

Image Description (Figure 03)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The graph shows mean change in peak flow rate (mL/sec) on the vertical axis over a 30-month period on the horizontal axis, with error bars and statistically significant points marked by asterisks.*

FDA Label Image

Label (Lbl713353131)

Label for Terazosin 5 mg capsules, USP, oral dosage form. The label indicates a package of 100 capsules, repackaged by Bryant Ranch Prepack in Burbank, CA, and manufactured by OrBion Pharmaceuticals Private Ltd. It includes storage instructions and a barcode with NDC 71335-3131-1.*

FDA Label Image

Image Description (Structure001)

Chemical structure of Terazosin hydrochloride dihydrate, showing its molecular framework with aromatic rings, amine groups, and piperazine and oxazolidinone moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.